Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
暂无分享,去创建一个
S. Madhi | S. Richardson | P. Moore | T. Moyo-Gwete | T. Rossouw | M. Boswell | T. Hermanus | F. Abdullah | V. Ueckermann | N. Manamela | Prudence Kgagudi | F. Ayres | Z. Makhado | H. Kaldine | B. Motsoeneng | M. A. van der Mescht
[1] D. Lauffenburger,et al. Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination , 2023, npj Vaccines.
[2] W. Bierman,et al. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study , 2022, PLoS medicine.
[3] S. Madhi,et al. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial , 2022, The Lancet Infectious Diseases.
[4] O. Hyrien,et al. Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19 , 2022, JCI insight.
[5] A. Meyerhans,et al. Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination , 2022, Frontiers in Immunology.
[6] C. Agrati,et al. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV , 2022, Nature Communications.
[7] T. Ndung’u,et al. HIV viremia is associated with compromised SARS-CoV-2 Beta variant neutralization. , 2022, The Journal of infectious diseases.
[8] T. de Oliveira,et al. Persistent SARS-CoV-2 infection with accumulation of mutations in a patient with poorly controlled HIV infection , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] D. Lauffenburger,et al. The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia , 2022, mBio.
[10] V. Calvez,et al. High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2 , 2022 .
[11] D. Podzamczer,et al. Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV , 2022, AIDS.
[12] J. Montaner,et al. People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses , 2022, The Journal of infectious diseases.
[13] C. Pade,et al. Generation of Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants on the B.1.1.7 Lineage in 3 Patients With Advanced Human Immunodeficiency Virus (HIV)-1 Disease , 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[14] N. Ford,et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 , 2022, The Lancet HIV.
[15] S. Madhi,et al. Influenza Vaccination Results in Differential Hemagglutinin Stalk-Specific Fc-Mediated Functions in Individuals Living With or Without HIV , 2022, Frontiers in Immunology.
[16] C. Agrati,et al. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count , 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[17] J. Andriesen,et al. High Asymptomatic Carriage With the Omicron Variant in South Africa , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] D. Lauffenburger,et al. mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions , 2022, Science Translational Medicine.
[19] M. Alcaide,et al. A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV , 2022, Frontiers in Medicine.
[20] D. Hagin,et al. SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center , 2022, Open forum infectious diseases.
[21] N. Sullivan,et al. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity , 2022, Cell Reports Medicine.
[22] D. Vézina,et al. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection , 2022, Cell Reports.
[23] T. Ndung’u,et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape , 2022, Cell Host & Microbe.
[24] T. Ndung’u,et al. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV) , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[25] M. Peluso,et al. Differences in Post-mRNA Vaccination SARS-CoV-2 IgG Concentrations and Surrogate Virus Neutralization Test Response by HIV Status and Type of Vaccine: a Matched Case-Control Observational Study. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] M. Peluso,et al. Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[27] D. Consonni,et al. Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study , 2021, The Lancet Regional Health - Europe.
[28] H. Bundgaard,et al. Humoral response to two doses of BNT162b2 vaccination in people with HIV , 2021, Journal of internal medicine.
[29] E. Wolf,et al. Humoral response to SARS-CoV-2 vaccines in people living with HIV , 2021, Infection.
[30] J. Montaner,et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy , 2021, medRxiv : the preprint server for health sciences.
[31] P. Klenerman,et al. Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses , 2021 .
[32] Kyle J. Hunter,et al. SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV , 2021, AIDS.
[33] T. Ndung’u,et al. Similar antibody responses against SARS-CoV-2 in HIV uninfected and infected individuals on antiretroviral therapy during the first South African infection wave. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] T. Ndung’u,et al. Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South African Infection Wave , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[35] S. Madhi,et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial , 2021, The Lancet HIV.
[36] V. Martel-Laferrière,et al. Covid-19 vaccine immunogenicity in people living with HIV-1 , 2021, bioRxiv.
[37] D. Lauffenburger,et al. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination , 2021, Cell Reports Medicine.
[38] R. Shafer,et al. SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA , 2021, Emerging infectious diseases.
[39] O. Laeyendecker,et al. The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV) , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] P. Klenerman,et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial , 2021, The Lancet HIV.
[41] H. Schuitemaker,et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.
[42] M. Peluso,et al. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study , 2021, The Lancet HIV.
[43] A. Casadevall,et al. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma , 2021, mBio.
[44] A. Huppert,et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1 , 2021, Clinical Microbiology and Infection.
[45] L. Morris,et al. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351) , 2021, The New England journal of medicine.
[46] F. Tanser,et al. Beyond HIV prevalence: identifying people living with HIV within underserved areas in South Africa , 2021, BMJ Global Health.
[47] L. Morris,et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, Nature Medicine.
[48] S. Rowland-Jones,et al. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV , 2021, Nature Communications.
[49] David R. Holtgrave,et al. COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State , 2021, JAMA network open.
[50] K. Liang,et al. People Living with HIV Easily lose their Immune Response to SARS-CoV-2: Result From A Cohort of COVID-19 Cases in Wuhan, China , 2021, Research square.
[51] James D. Allen,et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection , 2020, bioRxiv.
[52] Nguyen H. Tran,et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses , 2020, Nature Medicine.
[53] M. Davenport,et al. Decay of Fc-dependent antibody functions after mild to moderate COVID-19 , 2020, Cell Reports Medicine.
[54] K. Bhaskaran,et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform , 2020, The Lancet HIV.
[55] G. Koh. Faculty Opinions recommendation of Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[56] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[57] C. Sabin,et al. Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[58] C. Sabin,et al. Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[59] D. Lauffenburger,et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality , 2020, Cell.
[60] M. Nussenzweig,et al. Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo , 2020, bioRxiv.
[61] L. Morris,et al. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[62] Kira L. Newman,et al. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival , 2020, Immunity.
[63] D. Lauffenburger,et al. Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[64] R. Baric,et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.
[65] K. Kim,et al. What Is COVID-19? , 2020, Frontiers for Young Minds.
[66] G. Canderan,et al. Monocyte Dysfunction, Activation, and Inflammation After Long-Term Antiretroviral Therapy in an African Cohort , 2019, The Journal of infectious diseases.
[67] G. Alter,et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation , 2019, Journal of immunological methods.
[68] Jeffrey W. Eaton,et al. Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017 , 2019, Nature.
[69] L. Morris,et al. Measuring the ability of HIV-specific antibodies to mediate trogocytosis. , 2018, Journal of immunological methods.
[70] D. Rodríguez-Sanz,et al. Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.
[71] Peter J. Hogarth,et al. Dimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG , 2016, The Journal of Immunology.
[72] J. Margolick,et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation , 2015, AIDS.
[73] Jerome H. Kim,et al. Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines , 2014, Science Translational Medicine.
[74] M. Proschan,et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. , 2010, Blood.
[75] D. Irvine,et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.
[76] J. V. van Dissel,et al. Restoration of the antibody response upon rabies vaccination in HIV-infected patients treated with HAART , 2009, AIDS.
[77] L. McHugh. World Health Organization: A Fact Sheet , 1996 .
[78] OUP accepted manuscript , 2022, Clinical Infectious Diseases.
[79] M. Plana,et al. Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults. , 2010, HIV medicine.